Outlook Therapeutics, Inc.
DE ˙ DB
0,75 € ↑0,07 (11,08%)
2026-06-04
PREZZO DELLE AZIONI
SecurityDE:41O / Outlook Therapeutics, Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership3,806 shares
Latest Disclosed Value $ 783
Morgan Stanley reports 36.82% decrease in ownership of 41O / Outlook Therapeutics, Inc.

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 3,806 shares of Outlook Therapeutics, Inc. (DE:41O) valued at $657 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 6,024 shares of Outlook Therapeutics, Inc.. This represents a change in shares of -36.82% during the quarter. The current value of the position is $2,862 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F OUTLOOK THERAPEUTICS COM 69012T305 3,806 -2,218 -36.82 1 -100.00 0.0000
2026-05-27 2025-12-31 13F/A-1 OUTLOOK THERAPEUTICS COM 69012T305 6,024 5,249 677.29 10 0.0000
2026-02-13 2025-12-31 13F OUTLOOK THERAPEUTICS COM 69012T305 6,024 5,249 10 0.0000
2026-05-27 2025-09-30 13F/A-1 OUTLOOK THERAPEUTICS COM 69012T305 775 -424,824 -99.82 1 -100.00 0.0000
2025-11-14 2025-09-30 13F OUTLOOK THERAPEUTICS COM 69012T305 775 -424,824 1 0.0000
2025-08-15 2025-06-30 13F OUTLOOK THERAPEUTICS COM 69012T305 425,599 386,125 978.18 681 1,316.67 0.0000
2025-05-15 2025-03-31 13F OUTLOOK THERAPEUTICS COM 69012T305 39,474 -17,918 -31.22 48 -55.56 0.0000
2025-05-15 2024-12-31 13F/A-1 OUTLOOK THERAPEUTICS COM 69012T305 57,392 13,663 31.24 108 -53.65 0.0000
2025-02-14 2024-12-31 13F OUTLOOK THERAPEUTICS COM 69012T305 57,392 13,663 108 0.0000
2025-05-14 2024-09-30 13F/A-2 OUTLOOK THERAPEUTICS COM 69012T305 43,729 30,843 239.35 234 145.26 0.0000
2025-02-14 2024-09-30 13F/A-1 OUTLOOK THERAPEUTICS COM 69012T305 43,729 30,843 234 0.0000
2024-11-14 2024-09-30 13F OUTLOOK THERAPEUTICS COM 69012T305 43,729 30,843 234 0.0000
2025-05-14 2024-06-30 13F/A-2 OUTLOOK THERAPEUTICS COM 69012T305 12,886 913 7.63 95 -33.10 0.0000
2024-10-17 2024-06-30 13F/A-1 OUTLOOK THERAPEUTICS COM 69012T305 12,886 913 95 0.0000
2024-08-14 2024-06-30 13F OUTLOOK THERAPEUTICS COM 69012T305 12,886 913 95 0.0000
2024-10-17 2024-03-31 13F/A-2 OUTLOOK THERAPEUTICS COM 69012T305 11,973 -4,038 -25.22 143 787.50 0.0000
2024-08-16 2024-03-31 13F/A-1 OUTLOOK THERAPEUTICS COM 69012T305 11,973 -4,038 143 0.0000
2024-05-15 2024-03-31 13F OUTLOOK THERAPEUTICS COM 69012T305 11,973 -4,038 143 0.0000
2019-04-23 2018-09-30 13F/A-2 ONCOBIOLOGICS COM 68235M105 16,011 0 0.00 16 14.29 0.0000
2018-11-20 2018-09-30 13F/A-1 ONCOBIOLOGICS COM 68235M105 16,011 0 16 0.0000
2018-11-14 2018-09-30 13F ONCOBIOLOGICS COM 68235M105 16,011 0 16
2019-04-23 2018-06-30 13F/A-1 ONCOBIOLOGICS COM 68235M105 16,011 0 0.00 14 0.00 0.0000
2018-08-14 2018-06-30 13F ONCOBIOLOGICS COM 68235M105 16,011 0 14
2019-04-23 2018-03-31 13F/A-1 ONCOBIOLOGICS COM 68235M105 16,011 0 0.00 14 -33.33 0.0000
2018-05-14 2018-03-31 13F ONCOBIOLOGICS COM 68235M105 16,011 0 14
2019-04-23 2017-12-31 13F/A-1 ONCOBIOLOGICS COM 68235M105 16,011 300 1.91 21 -4.55 0.0000
2018-02-14 2017-12-31 13F ONCOBIOLOGICS COM 68235M105 16,011 300 21
2017-11-14 2017-09-30 13F ONCOBIOLOGICS COM 68235M105 15,711 -5,500 -25.93 22 4.76 0.0000
2017-08-11 2017-06-30 13F ONCOBIOLOGICS COM 68235M105 21,211 0 0.00 21 -63.16 0.0000
2017-05-22 2017-03-31 13F/A-1 ONCOBIOLOGICS COM 68235M105 21,211 6,311 42.36 57 26.67 0.0000
2017-05-12 2017-03-31 13F ONCOBIOLOGICS COM 68235M105 21,211 57
2017-02-22 2016-12-31 13F/A-1 ONCOBIOLOGICS COM 68235M105 14,900 -3,000 -16.76 45 -40.79 0.0000
2017-02-13 2016-12-31 13F ONCOBIOLOGICS COM 68235M105 14,900 45
2016-11-10 2016-09-30 13F ONCOBIOLOGICS COM 68235M105 17,900 7,900 79.00 76 123.53 0.0000
2016-08-12 2016-06-30 13F ONCOBIOLOGICS COM 68235M105 10,000 10,000 34 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.